

22 February 2024 EMA/CHMP/SAWP/85681/2024 Press Office

Scientific advice and protocol assistance

Adopted during the CHMP meeting 19-22 February 2024

Pre-authorisation: scientific advice and protocol assistance EMA centralised procedures

	1995-2023	2024	Overall total
Scientific Advice	6072	68	6140
Follow-up to Scientific Advice	1928	23	1951
Protocol Assistance	1343	15	1358
Follow-up to Protocol Assistance	719	9	728
EMA/EUnetHTA parallel consultation advice	165	0	165
Qualification of novel methodologies	228	6	234
	10455	122	10576

Outcome of the February 2024 CHMP meeting in relation to scientific advice procedures

Final scientific advice procedures

Substance	Intended indications	Type of request				Topic				
		New		Follow- up						
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit	
Chemical	Treatment of cutaneous T-cell lymphoma		X				X	х		
Biological	Treatment of sickle cell				x	Х	X	х	Х	
Advanced Therapy	Treatment of methylmalonic acidemia				х			х		



Substance	Intended indications	Type of request			Торіс				
		New		Foll up	ow-				
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit
Chemical	Treatment of acromegaly			X			х	X	
Chemical	Treatment of ovarian cancer	х						X	
Chemical	Treatment of heart failure			x				X	
Biological	Treatment of AMD			x		x		x	
Chemical	Treatment of lysosomal storage disorder		x					X	Х
Chemical	Treatment of Hidradenitis Suppurativa	х						X	
Chemical	Treatment of COVID-19	x				x			
Biological	Treatment of myelodysplastic syndromes		x					x	
Biological	Treatment of myelodysplastic syndromes		x					х	
Biological	Treatment of Neoplasm			x		x			
Advanced Therapy	Treatment of optic neuropathy				x	x			
Biological	Treatment of Crohn's Disease	x					x	х	
Biological	Treatment of Crohn's Disease	x					x	x	
Advanced Therapy	Treatment of Relapsed/refractory multiple myeloma	x						x	
Chemical	Treatment of non-small cell lung cancer			x				x	
Chemical	Treatment of complicated urinary tract infections (cUTI)			X				x	
Biological	Treatment of pulmonary disease	x						х	
Chemical	Treatment of of iron deficiency	x				x	x	x	
Chemical	Treatment of weight management	x				х			
Chemical	Treatment of amyotrophic lateral sclerosis		x			х	x	x	
Biological	Treatment of Immune system disease		x				x	x	
Chemical	Treatment of seizure		x					x	
Chemical	Treatment of nephropathy	x						x	
Biological	Treatment of Weight Management	x				x	x	х	

Substance	Intended indications	Type of reques		est	Topic				
		New		Foll up	ow-				
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit
Biological	Treatment of unresectable mCRC	X						Х	
Chemical	Treatment of chondrosarcoma	x						X	
Biological	Treatment of Asthma	x						x	
Chemical	Treatment of arthritis	x						х	
Chemical	Treatment of IPF and progressive PPF	x					x	х	
Biological	Treatment of Crohn's Disease	x					x	x	
Advanced Therapy	Treatment of plasma cell myeloma	x						x	
Biological	Treatment of pulmonary arterial hypertension				x			x	
Biological	Treatment of primary IgA nephropathy				х	x		х	
Biological	Treatment of NSCLC			x				х	
Biological	Treatment of myotonic disorders		x					х	
Biological	Treatment of osteoporosis	x				x		х	
Chemical	Treatment of lung disease		x				x	х	
Biological	Treatment of Primary progressive multiple sclerosis			x				x	
Biological	Treatment of Cancer Cachexia	x					x	х	
Chemical	Treatment of RSV disease	x						х	
Biological	Treatment of Anaemia	x						x	
Biological	Treatment of Alzheimer's disease	x					x	x	
Chemical	Treatment of cerebral malformations		x				x	х	
Biological	Treatment of metastatic UC	x				x		х	
Advanced Therapy	Treatment of dementia		×			х	х	x	
Advanced Therapy	Treatment of B-cell lymphomas	х				х	x	x	
Chemical	Treatment of osteosarcoma	x						x	
Qualification	Medical Tool								
Qualification	Medical Tool								

Substance	Intended indications	Type of request				Topic					
		New		Follow- up							
		SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit		
Qualification	Medical Tool										
Qualification	Medical Tool							x			
Qualification	Medical Tool										

SA: Scientific Advice PA: Protocol Assistance

The above-mentioned 55 Scientific Advice letters – 26 Initial Scientific Advice, 8 Follow-up Scientific Advice, 11 Protocol Assistance letters, 5 Follow-up Protocol Assistance, 5 Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advice were adopted at the 19-22 February 2024.

New requests for scientific advice procedures

The Committee accepted 56 new Requests for which the procedure started at the SAWP meeting held on 5-8 Feb 2024. The new requests are divided as follows: 30 Initial Scientific Advice, 14 Follow-up Scientific Advice, 5 Protocol Assistance letters, 5 Follow-up Protocol Assistance, 2 Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advice.